Work

Embryonic Stem Cell–Derived Cardiac Myocytes Are Not Ready for Human Trials

Year: 2014

Type: article

Abstract: Recently a preclinical report assessed the efficacy, safety, and feasibility of using human embryonic stem cells to regenerate infarcted myocardium in a non-human primate model. This commentary evaluates that study by pointing out key weaknesses, offering an alternative perspective, and summarizing major unresolved issues. Our conclusion is that significant challenges remain before human embryonic stem cells are ready for use in clinical trials.

Source: Circulation Research

DOI: 10.1161/circresaha.114.304616

Authors: Mark E. Anderson, Joshua Goldhaber, Steven R. Houser, Michel Puceat, Mark A. Sussman

Institutions: University of Iowa, Cedars-Sinai Medical Center, Inserm, San Diego State University, Cedars-Sinai Smidt Heart Institute, Temple University

Language: English

Topic: Pluripotent Stem Cells Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Heart, Lung, and Blood Institute

Awards: Antagonism of myocardial aging and senescence with Pim-1 kinase, Calcium Signaling, Metabolism, and EC Coupling in Heart, Restoring Mycocardial Healing, Cellular Biology of Cardiac Sodium-Calcium Exchange, Stem Cell Signaling in the Pathologically Challenged Myocardium, Beta-adrenergic signaling: double edged sword of myocardial repair, Cardioprotection by optimizing mTOR activity, Molecular Engineering of Damaged Myocardium To Enhance Regeneration And Repair, Regulation of Signal Transduction to Treat Heart Failure, Enhanced Myocardial Repair with CardioClusters and CardioChimeras

OpenAlex ID: W2148096460

FWCI: 4.234

Cites: 17

Cited by: 56

Related to: 10